Anthracene-9,10-diones as potential anticancer agents: Bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity

Journal of Medicinal Chemistry

Volumn 41, Issue 19, 1998, Pages 3748-3752

  Venitt, Stanley ^a   Crofton Sleigh, Christopher ^a   Agbandje, Mavis ^a,b   Jenkins, Terence C ^a,c   Neidle, Stephen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BISANTRENE; DOXORUBICIN; MITOXANTRONE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG STRUCTURE; ESCHERICHIA COLI; MALE; MUTAGENICITY; MUTATION; NONHUMAN; RAT; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTHRACENES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ESCHERICHIA COLI; MALE; MITOXANTRONE; MUTAGENS; MUTATION; RATS; SALMONELLA TYPHIMURIUM;

EID: 0032505178     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980167r     Document Type: Article

References (30)

1. Lown, J. W., Ed. Anthracycline and Anthracenedione-based Anticancer Agents; Elsevier: Amsterdam, 1988.
2. Gatto, B.; Zagotto, G.; Sissi, C.; Cera, C.; Uriarte, E.; Palù, G.; Capranico, G.; Palumbo, M. Peptidyl anthraquinones as potential antineoplastic drugs: Synthesis, DNA binding, redox cycling, and biological activity. J. Med. Chem. 1996, 39, 3114-3122.
3. Gandolfi, C. A.; Beggiolin, G.; Menta, E.; Palumbo, M.; Sissi, C.; Spinelli, S.; Johnson, F. Chromophore-modified antitumor anthracenediones: Synthesis, DNA binding and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]phthalazine-5,10-diones. J. Med. Chem. 1995, 38, 526-536.
4. Capranico, G.; de Isabella, P.; Tinelli, S.; Bigioni, M.; Zunino, F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 1993, 32, 3038-3046.
5. Palù, G.; Palumbo, M.; Antonello, C.; Meloni, G. A.; Marciani Magno, S. A search for potential antitumor agents: biological effects and DNA-binding of a series of anthraquinone derivatives. Mol. Pharmacol. 1986, 29, 211-217.
6. Palumbo, M.; Palù, G.; Gia, O.; Ferrazzi, E.; Gastaldi, S.; Antonello, C.; Meloni, G. A. Bis-substituted hydroxyanthracene-diones: DNA binding and biological activity. Anti-Cancer Drug Des. 1987, 1, 337-346.
7. Zagotto, G.; Uriarte, E.; Antonello, C.; Conconi, M. T.; Marciani Magno, S.; Palumbo, M. New hydroxy-amido-anthraquinones as potential antineoplastic drugs. Bioorg. Med. Chem. Lett. 1992, 2, 659-662.
8. Collier, D. A.; Neidle, S. Synthesis, Molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones. J. Med. Chem. 1988, 31, 847-857.
9. Agbandje, M.; Jenkins, T. C.; McKenna, R.; Reszka, A. P.; Neidle, S. Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. J. Med. Chem. 1992, 35, 1418-1429.
10. Tanious, F. A.; Jenkins, T. C.; Neidle, S; Wilson, W. D. Substituent position dictates the intercalative DNA-binding mode for anthracene-9,10-dione antitumor drugs. Biochemistry 1992, 31, 11632-11640.
11. Haq, I.; Ladbury, J. E.; Chowdhry, B. Z.; Jenkins, T. C. Molecular anchoring of duplex and triplex DNA by disubstituted anthracene-9,10-diones: calorimetric. UV melting and competition dialysis studies. J. Am. Chem. Soc. 1996, 118, 10693-10701.
12. Neidle, S.; Jenkins, T. C. Molecular modeling to study DNA intercalation by antitumor drugs. Methods Enzymol. 1991, 203, 433-459.
13. Fox, K. R.; Polucci, P.; Jenkins, T. C.; Neidle, S. A molecular anchor for stabilizing triple-helical DNA. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7887-7891.
14. Jenkins, T. C.; Polucci, P.; Reszka, A. P.; Kelland, L. R.; Neidle, S. To be published.
15. Sun, D.; Thompson, B.; Gathers, B. E.; Salazar, M.; Kerwin, S. M.; Trent, J. O.; Jenkins, T. C.; Neidle, S.; Hurley, L. H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40, 2113-2116. Perry, P. J.; Gowan, S. M.; Reszka, A. P.; Polucci, P.; Jenkins, T. C.; Kelland, L. R.; Neidle, S. J. Med. Chem.; in press.
16. Sun, D.; Thompson, B.; Gathers, B. E.; Salazar, M.; Kerwin, S. M.; Trent, J. O.; Jenkins, T. C.; Neidle, S.; Hurley, L. H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40, 2113-2116. Perry, P. J.; Gowan, S. M.; Reszka, A. P.; Polucci, P.; Jenkins, T. C.; Kelland, L. R.; Neidle, S. J. Med. Chem.; in press.
17. Glickman, B. W.; Kotturi, G.; de Boer, J.; Kusser, W. Molecular mechanisms of mutagenesis and mutational spectra. In: Environmental Mutagenesis; Phillips, D. H., Venitt, S., Eds.; Bios Scientific Publishers: Oxford, 1995; pp 33-59.
18. Venitt, S.; Crofton-Sleigh, C.; Forster, R. Bacterial mutation assays using reverse mutation. In Mutagenicity. A Practical Approach; (Venitt, S., Parry, J. M., Eds.; IRL Press: Oxford, 1984; pp 45-98.
19. Au, W. W.; Butler, M. A.; Matney, T. S.; Loo, T. L. Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin. Cancer Res. 1981, 41, 376-379.
20. Ferguson, L. R.; Baguley, B. C. Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test. Mutat. Res. 1988, 209, 57-62.
21. Harrington-Brock, K.; Parker, L.; Doerr, C.; Cimino, M. C.; Moore, M. M. Analysis of the genotoxicity of anthraquinone dyes in the mouse lymphoma assay. Mutagenesis 1991, 6, 35-41.
22. Tikkanen, L.; Matsushima, T.; Natori, S. Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat. Res. 1993, 116, 297-304.
23. Ferguson, L. R.; Baguley, B. C. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutat. Res. 1996, 355, 91-101.
24. Zunino, F.; Capranico, G. DNA topoisomerase II as the primary target of anti-cancer anthracyclines. Anti-Cancer Drug Des. 1990, 5, 307-317.
25. Capranico, G.; Palumbo, M.; Tinelli, S.; Mabilia, M.; Pozzan, A.; Zunino, F. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J. Mol. Biol. 1994, 235, 1218-1230.
26. Anderson, R. D.; Berger, N. A. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res. 1994, 309, 109-142.
27. Ferguson, L. R.; Denny, W. A. Frameshift mutagenesis by acridines and other reversibly binding DNA ligands. Mutagenesis 1990, 5, 529-540.
28. Kaiser, V. L.; Ripley, L. S. DNA nick processing by exonuclease and polymerase activities of bacteriophage T4 DNA polymerase accounts for acridine-induced mutation specificities in T4. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2234-2238.
29. Zagotto, G.; Moro, S.; Uriarte, E.; Ferrazzi, E.; Palù, G.; Palumbo, M. Amido analogues of mitoxantrone: physicochemical properties, molecular modeling, cellular effects and antineoplastic potential. Anti-Cancer Drug Des. 1997, 12, 99-112.
30. Ferguson, L. R.; Pearson, A. E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 1996, 355, 1-12.